華潤三九(000999.SZ):昆藥未來主要承擔老齡化方向產品研發
格隆匯12月12日丨華潤三九(000999.SZ)於近期進行投資者關係活動,就“公司研發投入方向?”,公司回覆稱,研發方向與公司戰略以及業務結構相匹配,策略上堅持仿創結合。CHC領域圍繞預防治療-康復全領域,推出滿足消費者自我診療需求的產品,陸續上市布洛芬混懸液等市場急需產品;處方藥領域主要圍繞重點治療領域進行產品管線規劃佈局。昆藥未來主要承擔老齡化方向產品研發,圍繞三七也開展了多個研發項目,未來研發資源會往老齡健康方向傾斜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.